Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Aviano – page 12

213 clinical trials in Aviano, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Aviano at a glance
213
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

213 trials in Aviano

Open in trial search

Non-small cell lung cancer metastatic

Not recruiting

Study comparing valemetostat tosylate plus pembrolizumab versus pembrolizumab alone in patients with advanced non-small cell lung cancer with high PD-L1 expression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Daiichi Sankyo Inc.

Colonoscopy

Not recruiting

Efficacy and Safety of Mannitol Compared to Plenvu for Bowel Preparation in Patients Undergoing Elective Colonoscopy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Macrogol 4000
  • Sponsor:Ntc S.r.l.

Non-small cell lung cancer+1

Not recruiting

Study of roginolisib, dostarlimab and docetaxel combination for patients with advanced non-small cell lung cancer who did not respond to previous immunotherapy and chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anhydrous Docetaxel
  • Sponsor:iOnctura SA

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing Acasunlimab and Pembrolizumab with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acasunlimab
  • Sponsor:Genmab A/S

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Non-small cell lung cancer metastatic

Not recruiting

Study of Eftilagimod Alfa with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Immutep

Follicular lymphoma

Not recruiting

Study on Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma Not Eligible for Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Fondazione Italiana Linfomi Ets

Diffuse large B-cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Ibrutinib with Rituximab-CHOP for Untreated Patients with Diffuse Large B-cell Lymphoma at High Risk

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Italiana Linfomi Ets

Follicular lymphoma

Not recruiting

Study Comparing Shortened vs Standard Chemotherapy with Rituximab for Initial Treatment of High Tumor Burden Follicular Lymphoma in Newly Diagnosed Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine
  • Sponsor:Fondazione Italiana Linfomi Ets

Triple negative breast cancer

Not recruiting

Study on Avelumab for Patients with High-Risk Triple Negative Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab
  • Sponsor:Universita Degli Studi Di Padova

Non-small cell lung cancer+1

Not recruiting

Study Comparing Zimberelimab and Domvanalimab with Chemotherapy to Pembrolizumab with Chemotherapy for Patients with Untreated Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Gilead Sciences Inc.

Neoplasm

Not recruiting

Study on Repotrectinib for Patients with Advanced Solid Tumors with ALK, ROS1, or NTRK1-3 Gene Changes

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Repotrectinib
  • Sponsor:Turning Point Therapeutics Inc.

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Aviano

What the registry says about research in the country

01 Lung Cancer Research

Innovative trials exploring new treatment combinations for non-small cell lung cancer (NSCLC), including studies of novel immunotherapy approaches and targeted therapies. Research focuses on improving outcomes for patients with advanced stages of the disease.

  • Immunotherapy combinations
  • Maintenance therapy strategies
  • Targeted molecular treatments
02 Breast Cancer Studies

Clinical investigations targeting hormone receptor-positive and triple-negative breast cancers, evaluating novel therapeutic combinations and treatment strategies for both early-stage and metastatic disease.

  • Advanced/metastatic treatments
  • Hormone therapy combinations
  • Targeted therapies
03 Colorectal Cancer Trials

Research examining innovative approaches for metastatic colorectal cancer, including studies of targeted therapies and immunotherapy combinations. Focus on personalized treatment strategies based on molecular profiles.

  • Molecular-targeted therapies
  • Immunotherapy approaches
  • Combination treatments
Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.